Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel…
Market Outlook Despite the broad availability of antidepressants and atypical antipsychotics approved to treat major depressive disorder (MDD), approximately one-third of these patients are…
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…
Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, followed by a first-line biologic, usually a TNF-α inhibitor. Patients refractory to one or more TNF-α…
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-ASAs, corticosteroids) are…
The primary goals of pharmacotherapy in UC are to induce remission during acute flares and to maintain long-term corticosteroid-free remission, once remission is achieved. UC treatment regimens are…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the…
MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…
Multiple label expansions of premium-priced agents and the launch of four novel therapies will fuel the significant growth of the multiple myeloma market over the ten-year forecast period. The…
Crohn’s disease (CD) is a chronic debilitating illness with limited effective treatment options, especially for patients with moderate to severe disease. Treatment options for CD include…
Ulcerative colitis (UC) affects approximately 1.75 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however,…
Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and…
Last Updated 18 December 2015 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis factor…
Four novel prescription weight-loss agents have launched in the United States since 2012: Vivus’s Qsymia (phentermine/topiramate ER), Arena Pharmaceuticals/Eisai’s Belviq (lorcaserin),…